Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601053 | 0.82 | POLB (0.55) | POLBKCNH2ALKRIPK1BMPR1B | |
| SCHEMBL1601082 | 0.80 | ALK (0.63) | POLBKCNH2ALKRIPK1ACVR1 | |
| SCHEMBL1601049 | 0.76 | ALK (0.47) | POLBKCNH2ALKRIPK1BMPR1B | |
| SCHEMBL19908274 | 0.74 | POLB (0.51) | POLBKCNH2RIPK1BMPR1BBMPR1A | |
| SCHEMBL1601026 | 0.74 | ALK (0.70) | ALKACVR1 | |
| SCHEMBL12574166 | 0.74 | NTRK1 (0.46) | POLBKCNH2ALKRIPK1MAP3K11 | |
| SCHEMBL1601378 | 0.74 | ALOX5AP (0.31) | — | |
| SCHEMBL1602485 | 0.73 | ALK (0.59) | KCNH2ALKACVR1 | |
| SCHEMBL1600276 | 0.73 | KCNH2 (0.45) | POLBKCNH2ALKRIPK1BMPR1B | |
| SCHEMBL1601725 | 0.72 | ALK (0.52) | POLBKCNH2ALKRIPK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | claimed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8080561-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7919502-B2 | Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100048576-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7601716-B2 | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | CEPHALON, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160204-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | POLB 4316/4885KCNH2 462/4885ALK 1/4885 |
| US-20100048576-A1 | PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS | ALK, MET, RET | POLB 4316/4885KCNH2 462/4885ALK 1/4885 |
| US-20080032972-A1 | Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors | ALK, MET, RET | POLB 4316/4885KCNH2 462/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.